Mirikizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Mirikizumab and local guidelines before prescribing.
Biologic (IL-23)
Mechanism
IL-23 monoclonal antibody.
Uses
Ulcerative colitis, Crohn disease.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Infections, headache, injection-site reactions.
Interactions
Live vaccines contraindicated.
Contraindications and cautions
Active TB
Monitoring
LFT, infection
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Screen for TB and hepatitis.
More from the textbook: uses, cautions and other points
- Ustekinumab ; risankizumab , mirikizumab , guselkumab | IL-12/23; IL-23 | Crohn's and UC; generally well tolerated; IV induction then SC maintenance
Gastroenterology: Anatomy Physiology Pharmacology - Ustekinumab , risankizumab , mirikizumab , guselkumab .
Gastroenterology: Inflammatory Bowel Disease - Ustekinumab / risankizumab / mirikizumab / guselkumab | IL-12/23 or IL-23 blockers; IV induction, then subcutaneous.
Gastroenterology: Inflammatory Bowel Disease - IL-12/23 and IL-23 | Ustekinumab; risankizumab, guselkumab, mirikizumab | Psoriasis, Crohn's, UC, psoriatic arthritis | Generally well tolerated; infections
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology